FASEB J. Pierce now sold as Thermo Scientific
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wigzell, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wigzell, H.

The FASEB Journal, Vol 5, 2406-2411, Copyright © 1991 by The Federation of American Societies for Experimental Biology

REVIEWS

Prospects for an HIV-vaccine

H Wigzell
Department of Immunology, Karolinska Institute, Stockholm, Sweden.

A vaccine against HIV is badly needed. In the average clinical situation the virus displays a low-rate capacity to transfer infection. The frequency is significantly below 1 per contact situation, that is, a single infectious unit is the normal cause of infection. The time to induce disease in the adult is between 5 and 10 years. These facts are considered positive in relation to producing an HIV vaccine to achieve sterilizing and/or protective immunity. A summary of animal and human HIV/SIV vaccine studies is made giving certain support for the prospects of producing an HIV vaccine.


This article has been cited by other articles:


Home page
 ScienceHome page
B. Haynes
Scientific and social issues of human immunodeficiency virus vaccine development
Science, May 28, 1993; 260(5112): 1279 - 1286.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by The Federation of American Societies for Experimental Biology.